From artificial intelligence to analytics advances, fintech is changing the wealth management industry. Pexels

Today's technologies have changed the wealth management industry by providing innovative tools to help empower clients and may allow a more productive and beneficial working relationship between financial advisers and their clients. Whether someone is saving for retirement, college, a new business, or travel, I have found that with new technologies, I am better able to communicate with my clients and help them meet their holistic investment goals.

It is an exciting time for wealth management. The industry is on the cutting edge of creating and adopting new technologies and innovations to empower financial advisers to engage and manage our clients' assets. Technologies such as artificial intelligence and risk analytics can provide financial advisers with a more complete picture of their clients' financial lives, which in turn helps us monitor progress and adjust course as needed.

Clients want a trusted adviser to guide them in meeting their financial goals, and now I am able to implement new technologies that help me provide a higher level of service. Using new platforms, I am able to provide real-time information and advice to my clients. I can use this technology to tailor information to their specific investments, how the market is affecting them, and determine what moves to recommend to help them get them closer to their financial goals.

With recent volatility in the market, having immediate, real-time information helps me to change direction within a client's portfolio if needed, and has been a true blessing. The risk analytics platform enables me to identify financial risks that my clients may be exposed to and allows us to quickly change course if necessary. It's a powerful way to engage. Communicating expeditiously and efficiently is important with all clients including those that have large, diversified portfolios.

Lastly, as some clients mature in age, I have begun working with them and their adult children. Together, we use technology applications to monitor the portfolio's progress to meeting the client's goals. The technological tools available within the wealth management industry have become a beneficial way to conduct business with these younger generations, especially Millennials.

As the world continues to incorporate additional technologies into all facets of life, the new tools available to wealth managers can be impactful. We can improve our relationships with clients, provide dependable information, and help guide their decisions so they may achieve their goals in life.

------

Margo Geddie is senior vice president and financial adviser with the wealth management division of Morgan Stanley in Houston.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”